$511 Million is the total value of Darwin Global Management, Ltd.'s 12 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 50.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| XLRN | Buy | ACCELERON PHARMA INC | $204,095,000 | +70.0% | 1,505,012 | +60.4% | 39.96% | +19.3% |
| BBIO | Buy | BRIDGEBIO PHARMA INC | $128,753,000 | +173.1% | 2,090,149 | +215.3% | 25.21% | +91.7% |
| FATE | Buy | FATE THERAPEUTICS INC | $112,967,000 | +30.4% | 1,370,133 | +43.8% | 22.12% | -8.5% |
| RLAY | New | RELAY THERAPEUTICS INC | $27,050,000 | – | 782,471 | +100.0% | 5.30% | – |
| ARVN | Buy | ARVINAS INC | $9,288,000 | +210.6% | 140,511 | +299.2% | 1.82% | +118.1% |
| MGNX | New | MACROGENICS INC | $9,115,000 | – | 286,195 | +100.0% | 1.78% | – |
| GBIO | Buy | GENERATION BIO CO | $6,243,000 | +11.7% | 219,358 | +11.2% | 1.22% | -21.7% |
| KROS | New | KEROS THERAPEUTICS INC | $5,348,000 | – | 86,887 | +100.0% | 1.05% | – |
| CCCC | Sell | C4 THERAPEUTICS INC | $5,180,000 | -31.6% | 140,034 | -38.7% | 1.01% | -52.0% |
| IMVT | Sell | IMMUNOVANT INC | $1,056,000 | -88.5% | 65,849 | -67.0% | 0.21% | -91.9% |
| INBX | Buy | INHIBRX INC | $998,000 | -17.2% | 49,709 | +36.1% | 0.20% | -42.0% |
| FULC | Sell | FULCRUM THERAPEUTICS INC | $587,000 | -18.2% | 49,868 | -18.7% | 0.12% | -42.5% |
| STOK | Exit | STOKE THERAPEUTICS INC | $0 | – | -6,000 | -100.0% | -0.10% | – |
| SRPT | Exit | SAREPTA THERAPEUTICS INC | $0 | – | -114,900 | -100.0% | -5.47% | – |
| MRTX | Exit | MIRATI THERAPEUTICS INC | $0 | – | -260,876 | -100.0% | -15.99% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-17
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| FATE THERAPEUTICS INC | 5 | Q4 2021 | 24.2% |
| KEROS THERAPEUTICS INC | 5 | Q1 2023 | 12.8% |
| INHIBRX INC | 5 | Q4 2021 | 3.9% |
| ACCELERON PHARMA INC | 4 | Q3 2021 | 63.4% |
| AMBRX BIOPHARMA INC | 4 | Q3 2023 | 67.5% |
| ARGENX SE | 4 | Q3 2023 | 70.2% |
| BRIDGEBIO PHARMA INC | 4 | Q3 2021 | 25.2% |
| FULCRUM THERAPEUTICS INC | 4 | Q4 2021 | 0.9% |
| ASTRAZENECA PLC | 3 | Q2 2022 | 100.0% |
| INTELLIA THERAPEUTICS INC | 3 | Q4 2021 | 48.6% |
View Darwin Global Management, Ltd.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 4 | 2023-06-28 |
| SC 13D/A | 2023-06-28 |
| SC 13D/A | 2023-05-25 |
| 13F-HR | 2023-05-15 |
| SC 13G | 2023-04-03 |
| 3 | 2023-03-08 |
View Darwin Global Management, Ltd.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.